Skip to content


    DEA Class;  Rx

    Common Brand Names; Gabitril

    • Anticonvulsants,Others

    Oral anticonvulsant for partial seizures; unique MOA; inhibits reuptake of GABA; a therapeutic range for plasma concentrations has not been established; does not appear to affect hepatic microsomal enzymes; close monitoring for emerging or worsening suicidal thoughts/behavior or depression is recommended.

    Indicated for the adjunctive treatment of partial seizures.


    Dizziness (26-30%)

    Asthenia (16-20%)

    Somnolence (16-20%)

    Nausea (11-15%)

    Abdominal pain (6-10%)

    Diarrhea (6-10%)

    Vomiting (6-10%)

    Nervousness (6-10%)

    Pharyngitis (6-10%)

    Tremor (6-10%)

    Insomnia (6-10%)

    Rash (1-5%)

    Pruritis (1-5%)

    Ataxia (1-5%)

    Confusion (1-5%)

    Speech d/o (1-5%)

    Paresthesia (1-5%)

    Depr’n (1-5%)

    Pain (1-5%)

    Increased appetite (1-5%)

    Hostility (1-5%)

    Nystagmus (1-5%)

    Bullous dermatitis

    Vision blurred

    Antiepileptic drugs (AED) increase risk of suicidal thoughts or behavior in patients taking them for any indication; patients treated with any AED for any indication should be monitored for emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior

    Risk of seizures if used in patients without epilepsy (when used off-label in psychiatric disorder); in nonepileptic patients who develop seizures while on therapy, discontinue therapy and evaluate patients for underlying seizure disorder

    Should not be abruptly discontinued because of possibility of increasing seizure frequency

    Use without enzyme-inducing antiepileptic drugs results in about twice the blood levels than what dosage recommendations are based on

    Because clearance of tiagabine is reduced in patients with liver disease, dosage reduction may be necessary in these patients

    Adverse events most often associated with therapy were related to central nervous system; the most significant of these can be classified into 2 general categories: 1) impaired concentration, speech or language problems, and confusion (effects on thought processes); and 2) somnolence and fatigue (effects on level of consciousness)

    Moderately severe to incapacitating generalized weakness reported; resolves after reduction in dose or discontinuation of thearpy

    Pregnancy Category: C

    Lactation: Unknown; use caution


    56 mg/day PO, dependent on concomitant drug therapy.


    56 mg/day PO, dependent on concomitant drug therapy.


    >=12 years: 32 mg/day PO, dependent on concomitant drug therapy.


    2—11 years: 0.6—1 mg/kg/day PO suggested, dependent on concomitant drug therapy.

    Tiagabine Hydrochloride


    • 2mg
    • 4mg
    • 12mg
    • 16mg